6 Literaturverzeichnis

1. Gleason DF. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr 1988;15-8.

2. Leitlinien der Deutschen Urologen. PSA-Bestimmung in der Prostatakarzinomdiagnostik (Früherkennung des Prostatakarzinoms). AWMF online 2002;http://www.uni-duesseldorf.de/www/AWMF/ll/043-036v.htm [Stand:15.12.2005].

3. Stearns ME, Stearns M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer. Oncol Res 1996;8:63-7.

4. Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 1997;74:220-3.

5. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997;15:246-58.

6. Yousef GM, Stephan C, Scorilas A, Ellatif MA, Jung K, Kristiansen G, Jung M, Polymeris ME, Diamandis EP. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 2003;56:287-92.

7. Bussemakers MJ, van BA, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.

8. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-8.

9. Hessels D, Klein Gunnewiek JM, van O, I, Karthaus HF, van Leenders GJ, van BB, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.

10. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 2003;62:34-43.

11. Tinzl M, Marberger M, Horvath S, Chypre C. DD3(PCA3) RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 2004;46:182-6.

12. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002;10:311-22.

13. Sachs MD, Ramamurthy M, Poel H, Wickham TJ, Lamfers M, Gerritsen W, Chowdhury W, Li Y, Schoenberg MP, Rodriguez R. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 2004;11:477-86.

14. Ferrer FA, Rodriguez R. Gene therapy for urologic cancer. Curr Urol Rep 2002;3:75-81.

15. German Society of Urology. Guidelines for diagnosis of bladder cancer. Urologe A 1998;37:441-57.

16. Bianco FJ, Jr., Gervasi DC, Tiguert R, Grignon DJ, Pontes JE, Crissman JD, Fridman R, Wood DP, Jr. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res 1998;4:3011-6.

17. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993;53:5365-9.

18. Kanayama H. Matrix metalloproteinases and bladder cancer. J Med Invest 2001;48:31-43.

19. Papathoma AS, Petraki C, Grigorakis A, Papakonstantinou H, Karavana V, Stefanakis S, Sotsiou F, Pintzas A. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 2000;20:2009-13.

20. Dalbagni G, Reuter VE, Sheinfeld J, Fradet Y, Fair WR, Cordon-Cardo C. Cell surface differentiation antigens of normal urothelium and bladder tumors. Semin Surg Oncol 1992;8:293-9.

21. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005;116:100-4.

22. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8.

23. Christoph F, Muller M, Schostak M, Soong R, Tabiti K, Miller K. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology 2004;64:157-61.

24. Grotzer MA, Patti R, Geoerger B, Eggert A, Chou TT, Phillips PC. Biological stability of RNA isolated from RNAlater-treated brain tumor and neuroblastoma xenografts. Med Pediatr Oncol 2000;34:438-42.

25. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997;22:176-81.

26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.

27. Karge WH, III, Schaefer EJ, Ordovas JM. Quantification of mRNA by polymerase chain reaction (PCR) using an internal standard and a nonradioactive detection method. Methods Mol Biol 1998;110:43-61.

28. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169-93.

29. Suzuki T, Higgins PJ, Crawford DR. Control selection for RNA quantitation. Biotechniques 2000;29:332-7.

30. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.

31. Meijerink J, Mandigers C, van de LL, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 2001;3:55-61.

32. Pfaffl MW. Real-time RT-PCR: Neue Ansätze zur exakten mRNA Quantifizierung. Biospektrum 2004; Sonderausgabe PCR, 10:92-5.

33. Zhong H, Simons JW. Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun 1999;259:523-6.

34. Schmittgen TD, Zakrajsek BA. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 2000;46:69-81.

35. Goidin D, Mamessier A, Staquet MJ, Schmitt D, Berthier-Vergnes O. Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and beta-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal Biochem 2001;295:17-21.

36. Bhatia P, Taylor WR, Greenberg AH, Wright JA. Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene expression as RNA loading controls for northern blot analysis of cell lines of varying malignant potential. Anal Biochem 1994;216:223-6.

37. Bereta J, Bereta M. Stimulation of glyceraldehyde-3-phosphate dehydrogenase mRNA levels by endogenous nitric oxide in cytokine-activated endothelium. Biochem Biophys Res Commun 1995;217:363-9.

38. Zhang J, Snyder SH. Nitric oxide stimulates auto-ADP-ribosylation of glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci U S A 1992;89:9382-5.

39. Schmid H, Cohen CD, Henger A, Irrgang S, Schlondorff D, Kretzler M. Validation of endogenous controls for gene expression analysis in microdissected human renal biopsies. Kidney Int 2003;64:356-60.

40. Singh R, Green MR. Sequence-specific binding of transfer RNA by glyceraldehyde-3-phosphate dehydrogenase. Science 1993;259:365-8.

41. Ishitani R, Sunaga K, Hirano A, Saunders P, Katsube N, Chuang DM. Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem 1996;66:928-35.

42. Selvey S, Thompson EW, Matthaei K, Lea RA, Irving MG, Griffiths LR. Beta-actin--an unsuitable internal control for RT-PCR. Mol Cell Probes 2001;15:307-11.

43. Glare EM, Divjak M, Bailey MJ, Walters EH. beta-Actin and GAPDH housekeeping gene expression in asthmatic airways is variable and not suitable for normalising mRNA levels. Thorax 2002;57:765-70.

44. Yuan SS, Chung YF, Chen HW, Tsai KB, Chang HL, Huang CH, Su JH. Aberrant expression and possible involvement of the leptin receptor in bladder cancer. Urology 2004;63:408-13.

45. Tricarico C, Pinzani P, Bianchi S, Paglierani M, Distante V, Pazzagli M, Bustin SA, Orlando C. Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies. Anal Biochem 2002;309:293-300.

46. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002;29:23-39.

47. Deindl E, Boengler K, van Royen N, Schaper W. Differential expression of GAPDH and beta3-actin in growing collateral arteries. Mol Cell Biochem 2002;236:139-46.

48. Hamalainen HK, Tubman JC, Vikman S, Kyrola T, Ylikoski E, Warrington JA, Lahesmaa R. Identification and validation of endogenous reference genes for expression profiling of T helper cell differentiation by quantitative real-time RT-PCR. Anal Biochem 2001;299:63-70.

49. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 2004;37:112-9.

50. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.1-RESEARCH0034.11.

51. Thellin O, Zorzi W, Lakaye B, De BB, Coumans B, Hennen G, Grisar T, Igout A, Heinen E. Housekeeping genes as internal standards: use and limits. J Biotechnol 1999;75:291-5.

52. Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 2004;313:856-62.

53. Bas A, Forsberg G, Hammarstrom S, Hammarstrom ML. Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scand J Immunol 2004;59:566-73.

54. Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 2005;21:389-95.

55. Gorzelniak K, Janke J, Engeli S, Sharma AM. Validation of endogenous controls for gene expression studies in human adipocytes and preadipocytes. Horm Metab Res 2001;33:625-7.

56. Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett 2004;26:509-15.

57. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004;64:5245-50.

58. Haller F, Kulle B, Schwager S, Gunawan B, von HA, Sultmann H, Fuzesi L. Equivalence test in quantitative reverse transcription polymerase chain reaction: confirmation of reference genes suitable for normalization. Anal Biochem 2004;335:1-9.

59. Szabo A, Perou CM, Karaca M, Perreard L, Quackenbush JF, Bernard PS. Statistical modeling for selecting housekeeper genes. Genome Biol 2004;5:R59.

60. Lupberger J, Kreuzer KA, Baskaynak G, Peters UR, le CP, Schmidt CA. Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR. Mol Cell Probes 2002;16:25-30.

61. Janssens N, Janicot M, Perera T, Bakker A. Housekeeping genes as internal standards in cancer research. Mol Diagn 2004;8:107-13.

62. Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro V, Smith K, Hu N, Su H, Taylor PR, Marincola FM, Wang E. Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics 2004;5:55.

63. National Center for Biotechnology Information, U.S.National Library of Medicine. Medline-Datenbank Pubmed. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed [Stand:15.12.2005]

64. Nagler DK, Kruger S, Kellner A, Ziomek E, Menard R, Buhtz P, Krams M, Roessner A, Kellner U. Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia. Prostate 2004;60:109-19.

65. Katenkamp K, Berndt A, Hindermann W, Wunderlich H, Haas KM, Borsi L, Zardi L, Kosmehl H. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J Pathol 2004;203:771-9.

66. Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res 2004;64:9185-92.

67. Tian W, Osawa M, Horiuchi H, Tomita Y. Expression of the prolactin-inducible protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate. Cancer Sci 2004;95:491-5.

68. Wang H, Xi X, Kong X, Huang G, Ge G. The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 2004;130:487-90.

69. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, Saccani G, Frati L, Agliano AM. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003;14:85-90.

70. Nomura T, Nakagawa M, Fujita Y, Hanada T, Mimata H, Nomura Y. Clinical significance of thymidylate synthase expression in bladder cancer. Int J Urol 2002;9:368-76.

71. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, Ince TA, McKeon FD, Cordon-Cardo C. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002;161:1199-206.

72. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003;163:505-16.

73. Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer 2003;89:2172-7.

74. Nawrocki S, Skacel T, Brodowicz T. From microarrays to new therapeutic approaches in bladder cancer. Pharmacogenomics 2003;4:179-89.

75. Suhr J, Eisenhardt A, Schmid KW, vom DF, Otto T. Biochips in bladder cancer research. Urologe A 2003;42:927-32.

76. Almeida A, Paul TJ, Magdelenat H, Radvanyi F. Gene expression analysis by real-time reverse transcription polymerase chain reaction: influence of tissue handling. Anal Biochem 2004;328:101-8.

77. Sobin LH, Wittekind C. TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss, 2002:184-7.

78. Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003;54:34-43.

79. Staack A, Tolic D, Kristiansen G, Schnorr D, Loening SA, Jung K. Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. Urology 2004;63:1089-94.

80. Mueller O, Lightfoot S, Schroeder A. RNA Integrity Number (RIN) - Standardization of RNA Quality Control. Agilent Technologies 2004;

81. Miller CL, Diglisic S, Leister F, Webster M, Yolken RH. Evaluating RNA status for RT-PCR in extracts of postmortem human brain tissue. Biotechniques 2004;36:628-33.

82. Imbeaud S, Graudens E, Boulanger V, Barlet X, Zaborski P, Eveno E, Mueller O, Schroeder A, Auffray C. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res 2005;33:e56.

83. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.

84. Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol 1986;51 Pt 1:263-73.

85. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001.

86. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.

87. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-10.

88. Birney E, Andrews TD, Bevan P, Caccamo M, Chen Y, Clarke L, Coates G, Cuff J, Curwen V, Cutts T, Down T, Eyras E, Fernandez-Suarez XM, Gane P, Gibbins B, Gilbert J, Hammond M, Hotz HR, Iyer V, Jekosch K, Kahari A,

Kasprzyk A, Keefe D, Keenan S, Lehvaslaiho H, et al. An overview of Ensembl. Genome Res 2004;14:925-8.

89. Rasmussen R. Quantification on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K, eds. Rapid Cycle Real-time PCR, Methods and Applications. Heidelberg: Springer Press, 2001:21-34.

90. Livak KJ. ABI Prism 7700 Sequence detection Sysstem: User Bulletin Nr.2 Relative quantification of gene expression. http://docs.appliedbiosystems.com/pebiodocs/04303859.pdf [Stand:15.12.2005]

91. Dechert U. Gelelektrophorese von Nukleinsäuren. In: Schrimpf G, ed. Gentechnische Methoden: eine Sammlung von Arbeitsanleitungen für das molekularbiologische Labor. 3.Aufl. Heidelberg; Berlin: Spektrum, Akad.Verl., 2002:66-88.

92. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. GeNorm software manual, update 6 Sep 2004. http://medgen.ugent.be/~jvdesomp/genorm [Stand:15.12.2005]

93. Passing H, Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983;21:709-20.

94. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem 1997;245:154-60.

95. Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 1998;24:954-8, 960, 962.

96. Bullock GC, Bruns DE, Haverstick DM. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin Chem 2002;48:2147-54.

97. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 2005;85:154-9.

98. Wernert N. Laser microdissection in the molecular oncology of prostate cancer. Urologe A 2004;43:646-52.

99. Lin VK, Wang SY, Boetticher NC, Vazquez DV, Saboorian H, McConnell JD, Roehrborn CG. Alpha(2) macroglobulin, a PSA binding protein, is expressed in human prostate stroma. Prostate 2005;63:299-308.

100. Wang WH, McNatt LG, Shepard AR, Jacobson N, Nishimura DY, Stone EM, Sheffield VC, Clark AF. Optimal procedure for extracting RNA from

human ocular tissues and expression profiling of the congenital glaucoma gene FOXC1 using quantitative RT-PCR. Mol Vis 2001;7:89-94.

101. Medeiros M, Sharma VK, Ding R, Yamaji K, Li B, Muthukumar T, Valderde-Rosas S, Hernandez AM, Munoz R, Suthanthiran M. Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater. J Immunol Methods 2003;279:135-42.

102. Wilhelm J, Pingoud A. Real-time polymerase chain reaction. Chembiochem 2003;4:1120-8.

103. Jung M, Xu C, Ohl F, Mager AK, Jung K. Transcriptor first strand cDNA synthesis kit: efficient and fast-a comparison to other kits. Biochemica Roche Applied Science 2005;2:16-8.

104. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 2000;285:194-204.

105. Marino JH, Cook P, Miller KS. Accurate and statistically verified quantification of relative mRNA abundances using SYBR Green I and real-time RT-PCR. J Immunol Methods 2003;283:291-306.

106. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36.

107. Wittwer CT, Fillmore GC, Hillyard DR. Automated polymerase chain reaction in capillary tubes with hot air. Nucleic Acids Res 1989;17:4353-7.

108. Gerard CJ, Olsson K, Ramanathan R, Reading C, Hanania EG. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res 1998;58:3957-64.

109. Nitsche A, Steuer N, Schmidt CA, Landt O, Siegert W. Different real-time PCR formats compared for the quantitative detection of human cytomegalovirus DNA. Clin Chem 1999;45:1932-7.

110. Nelson PS. Predicting prostate cancer behavior using transcript profiles. J Urol 2004;172:S28-S32.

111. Mutimer H, Deacon N, Crowe S, Sonza S. Pitfalls of processed pseudogenes in RT-PCR. Biotechniques 1998;24:585-8.

112. Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 1995;159:43-7.

113. Tschentscher P, Wagener C, Neumaier M. Sensitive and specific cytokeratin 18 reverse transcription-polymerase chain reaction that excludes amplification of processed pseudogenes from contaminating genomic DNA. Clin Chem 1997;43:2244-50.

114. Garcia-Meunier P, Etienne-Julan M, Fort P, Piechaczyk M, Bonhomme F. Concerted evolution in the GAPDH family of retrotransposed pseudogenes. Mamm Genome 1993;4:695-703.

115. Kim S, Kim T. Selection of optimal internal controls for gene expression profiling of liver disease. Biotechniques 2003;35:456-8, 460.

116. Savli H, Karadenizli A, Kolayli F, Gundes S, Ozbek U, Vahaboglu H. Expression stability of six housekeeping genes: A proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR. J Med Microbiol 2003;52:403-8.

117. Biederman J, Yee J, Cortes P. Validation of internal control genes for gene expression analysis in diabetic glomerulosclerosis. Kidney Int 2004;66:2308-14.

118. Ontsouka EC, Reist M, Graber H, Blum JW, Steiner A, Hirsbrunner G. Expression of messenger RNA coding for 5-HT receptor, alpha and beta adrenoreceptor (subtypes) during oestrus and dioestrus in the bovine uterus. J Vet Med A Physiol Pathol Clin Med 2004;51:385-93.

119. Hoerndli FJ, Toigo M, Schild A, Gotz J, Day PJ. Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. Anal Biochem 2004;335:30-41.

120. Radonic A, Thulke S, Bae HG, Muller MA, Siegert W, Nitsche A. Reference gene selection for quantitative real-time PCR analysis in virus infected cells: SARS corona virus, Yellow fever virus, Human Herpesvirus-6, Camelpox virus and Cytomegalovirus infections. Virol J 2005;2:7.

121. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, Ide C, Horan TP, Arakawa T, Yoshida H, Nishikawa S, Itoh Y, Seiki M, Itohara S, Takahashi C, Noda M. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001;107:789-800.

122. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara RM, Horimoto A, Ikawa Y, Ratzkin BJ, Arakawa T, Noda M. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A 1998;95:13221-6.

123. Masui T, Doi R, Koshiba T, Fujimoto K, Tsuji S, Nakajima S, Koizumi M, Toyoda E, Tulachan S, Ito D, Kami K, Mori T, Wada M, Noda M, Imamura M. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res 2003;9:1779-84.

124. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 2005;92:2171-80.

125. Rabien A, Burkhardt M, Jung M, Fritzsche F, Ohl F, Ringsdorf M, Schicktanz H, Loening S, Kristiansen G, Jung K. Decreased expression of the tumor suppressor RECK: a novel long-term prognosis factor for prostate cancer. Prostate 2005;Manuskript eingereicht im November 2005:

126. Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LF, Lein M, Sinha P, Loening SA, Jung K. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002;48:1279-87.